Euploidy rates in donor egg cycles significantly differ between fertility centers.
Do external factors affect euploidy in egg donor cycles?



The study demonstrates that during human assisted reproduction, embryonic chromosome abnormalities may be partly iatrogenic.



Chromosome abnormalities have been linked in the past to culture conditions such as temperature and Ph variations, as well as hormonal stimulation. Those reports were performed with older screening techniques (FISH), or ART methods no longer in use, and the subjects studied were not a homogeneous group.



A total of 1645 donor oocyte cycles and 13 282 blastocyst biopsies from 42 fertility clinics were included in this retrospective cohort study. Samples from donor cycles with PGS attempted between September 2011 and July 2015 were included.



PGS cycles from multiple fertility clinics referred to Reprogenetics (Livingston, NJ) that involved only oocyte donation were included in this study. Testing was performed by array comparative genomic hybridization (aCGH). Ploidy data were analyzed using Generalized Linear Mixed Models with logistic regression using a logit link function considering a number of variables that represent fixed and random effects.



Euploidy rate was associated with the referring center and independent of almost all the parameters examined except donor age and testing technology. Average euploidy rate per center ranged from 39.5 to 82.5%. The mean expected rate of euploidy was 68.4%, but there are variations in this rate associated with the center effect.



Data set does not include details of the donor selection process, donor race or ethnic origin, ovarian reserve or ovarian responsiveness. Due to the retrospective nature of the study, associations are apparent, however, causality cannot be established. Discrepancies in regard to completeness and homogeneity of data exist due to data collection from over 40 different clinics.



This is the first study to show a strong association between center-specific ART treatment practices and the incidence of chromosome abnormality in human embryos, although the meiotic or mitotic origin of these abnormalities could not be determined using these technologies. Given the widespread applications of ART in both subfertile and fertile populations, our findings should be of interest to the medical community in general as well as the ART community in particular.



No external funds were used for this study. S. Munne is a founding principle of Reprogenetics/current employee of Cooper Genomics. M Alikani's spouse is a founding principle of Reprogenetics/current consultant for Cooper Genomics. The remaining authors have no conflicts to declare.
Reprogenetics, Livingston, NJ, USA.
S
S
Munné
Reproductive Science Center of New Jersey, Eatontown, NJ, USA.
M
M
Alikani
Reprogenetics, Livingston, NJ, USA.
L
L
Ribustello
Reprogenetics, Livingston, NJ, USA.
P
P
Colls
University of Alicante, Carretera San Vicente s/n, San Vicent del Raspeig, Alicante, Spain.
Pedro A
PA
Martínez-Ortiz
NYU Langone Medical Center, NYU Fertility Center, New York, NY, USA.
D H
DH
McCulloh
D000328:Adult; D002869:Chromosome Aberrations / Q000196:embryology*; D055028:Comparative Genomic Hybridization; D019924:Embryo Disposition / Q000592:standards; D005260:Female; D005298:Fertility; D006801:Humans; D018587:Oocyte Donation / Q000592:standards; D011003:Ploidies; D017410:Practice Guidelines as Topic; D019836:Preimplantation Diagnosis; D027724:Reproductive Techniques, Assisted / Q000592:standards*; D012189:Retrospective Studies
ART; PGS; aneuploidy; donor oocytes; euploidy; mosaicism